Christian Lienhardt, from WHO, discusses the launch of TB-PACTS, the new data-sharing platform for TB clinical trials. This marks the beginning of an exciting new tool in the fight against TB. Announced on April 18th, TB-PACTS combines clinical trial data from Critical Path Institute (C-Path), the Special Programme for Research and Training in Tropical Diseases [...]
Tuberculosis continues to become more resistant to existing drug regimens resulting in a need for constant innovation on the part of drug researchers. In an article published by Medicalxpress.com which can be found here, researchers are reported to have found a chemical alteration that makes fluoroquinolones, an existing group of TB-fighting drugs, more effective against [...]
Cape Town, South Africa, Dec. 5, 17:30 – 20:30 We invite you to join us for the Stop TB Partnership Working Group on New Drugs’ Annual Meeting 2015 at Southern Sun Cape Sun Hotel, Cape Town, South Africa, on Saturday, Dec. 5th from 17:30 to 20:30. This meeting is held before the 46th Union World Conference on [...]
Worldwide, governments, foundations, and companies invested US$676.7 million in research to develop new drugs, vaccines, and diagnostics against tuberculosis (TB) in 2013—barely one-third of the US$2 billion that experts estimate the world must spend each year to end the global TB epidemic—according to an analysis released today by Treatment Action Group (TAG).
Results of the Phase III REMoxTB clinical trial were published in the New England Journal of Medicine on September 7th, 2014. REMox or Rapid Evaluation of Moxifloxacin in Tuberculosis (REMoxTB) was a trial designed to determine whether replacement of either ethambutol or isoniazid with moxifloxacin shortened the duration of therapy. In summary, while the regimens with moxifloxacin caused a [...]